Despite the fact that HER2-positive/hormone receptor positive tumors have nowadays a prognosis similar to that of luminal B breast cancer (89), patients bearing IMPC exhibited a poor response to trastuzumab in the adjuvant setting (262). Here, ERBB2 is linked to breast carcinoma.